drugset / Trial / NCT01809691

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

NCT01809691

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.

Timeline

Start
2013-03-08
Primary completion
2022-03-08
Completion
2025-09-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bicalutamide Other / unclassified 50 mg Oral
Subject Orteronel Small molecule 300 mg Oral

Indications